title: Standard and new treatments in cutaneous B-cell lymphomas.
abstract: BACKGROUND
  Primary cutaneous B-cell lymphomas (PCBCL) are cutaneous non-Hodgkin lymphomas and can be classified clinically and by prognosis. The aim of this paper is to perform a review of standard and new treatments.
  
  
  METHODS
  This paper provides a literature review of the different treatments of PCBCL.
  
  
  RESULTS
  Surgery and radiotherapy remain the standard therapies in isolated cutaneous lesions. Systemic or intralesional interferon (IFN)-alpha may be an alternative in PCBCL with diffuse cutaneous lesions. In aggressive forms with poor prognosis, polychemotherapy is the first line of treatment although rituximab and radioimmunotherapy are evolving therapeutic options.
  
  
  CONCLUSIONS
  In the majority of cases, the treatment of CBCL is straightforward. In aggressive forms, new therapies and biologic therapies may be of real interest.
authors.affiliation: Department of Dermatology, CHU Hôtel Dieu, Nantes, France. brigitte.dreno@wanadoo.fr
authors.forename: Brigitte
authors.initials: B
authors.lastname: Dreno
mesh_terms: D003131:Combined Modality Therapy; D006801:Humans; D016393:Lymphoma, B-Cell / Q000473:pathology / Q000628:therapy*; D012878:Skin Neoplasms / Q000473:pathology / Q000628:therapy*